Pharmaceutical

ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam

Alnylam announced positive final results from the Helios-B trial for patients with ATTR amyloidosis with cardiomyopathy at the ESC Congress.

Aug 31, 2024 - 04:00
ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam
Alnylam announced positive final results from the Helios-B trial for patients with ATTR amyloidosis with cardiomyopathy at the ESC Congress.
Read the original article

Tags:

Previous Article

J&J targets generalised myasthenia gravis landscape with nipocalimab

Next Article

ESC 2024: Obesity drugs emerge as attractive tool for heart failure prevention

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca scores its second paediatric approval for Soliris in Japan

AstraZeneca scores its second paediatric approval for S...

Aug 26, 2023

As NIH grant runs out, Dog Aging Project founders look to raise up to $50 million

As NIH grant runs out, Dog Aging Project founders look ...

Jan 24, 2024

Swiss biotech ecosystem recuperates from global financial instability

Swiss biotech ecosystem recuperates from global financi...

Jun 2, 2024